SCHEMBL4677162

SCHEMBL4677162

COc1ccc(Cc2sccc2C(=O)/C=C(\O)C(=O)O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.42
RAB9A P51151 1/20 0.42
MAPK8 P45983 1/20 0.42
ALDH1A1 P00352 3/20 0.41
HPGD P15428 1/20 0.41
LTB4R Q15722 1/20 0.41
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
SAE1 Q9UBE0 1/20 0.39
UBA2 Q9UBT2 1/20 0.39
ABL1 P00519 1/20 0.39
LTA4H P09960 1/20 0.39
LMNA P02545 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPT P10636 1/20 0.38
LDHA P00338 1/20 0.38
POLB P06746 2/20 0.38
CTBP2 P56545 1/20 0.38
GAA P10253 1/20 0.38
ALOX12 P18054 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4677166 1.00 NPC1 (0.42) NPC1RAB9AMAPK8ALDH1A1HPGD
SCHEMBL4673873 0.86 MAPK8 (0.39) NPC1RAB9AMAPK8ALDH1A1HPGD
SCHEMBL4673876 0.86 MAPK8 (0.39) NPC1RAB9AMAPK8ALDH1A1HPGD
SCHEMBL4673936 0.84 PTPN1 (0.38) NPC1RAB9AMAPK8ALDH1A1HPGD
SCHEMBL4673929 0.84 PTPN1 (0.38) NPC1RAB9AMAPK8ALDH1A1HPGD
SCHEMBL4676734 0.84 KMT2A (0.45) NPC1RAB9AALDH1A1TSHRLMNA
SCHEMBL4676730 0.84 KMT2A (0.45) NPC1RAB9AALDH1A1TSHRLMNA
SCHEMBL4674868 0.83 MAPK8 (0.39) NPC1RAB9AMAPK8ALDH1A1HPGD
SCHEMBL4674863 0.83 MAPK8 (0.39) NPC1RAB9AMAPK8ALDH1A1HPGD
SCHEMBL4671796 0.83 ITGB1 (0.35) NPC1RAB9AALDH1A1HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 NPC1 934/4885RAB9A 2021/4885MAPK8 2178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.